Intraocular injection conbercept is safe and effective to improve vision, relieve symptoms for patients suffered from choroidal neovascularization secondary to punctate inner choroidopathy

Not Applicable

Completed

• Conditions: Active subfoveal or juxatoveal CNV secondary to punctate inner choroidopathy; Eye Diseases

• Registration Number: ISRCTN85678307
• Lead Sponsor: Zhongshan Ophthalmic Center

Brief Summary

1. 2017 results in https://www.ncbi.nlm.nih.gov/pubmed/28606070 (added 31/01/2019)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2016-11-26
• Study Start: 2017-05-11
• Last Update Posted: 11 February 2019

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

1. Active subfoveal or juxatoveal CNV secondary to PIC, where PIC was defined as multiple, small yellow-white lesions or atrophy in the posterior pole that had typical manifestations on optical coherence tomography (OCT) images
2. PIC lesions observed around the CNV. CNV was considered active if leakage within the lesion are observed with fluorescein angiography (FA) or intraretinal edema or subretinal fluid was observed with OCT
3. Adults aged 18 and older

Exclusion Criteria

1. CNV was secondary to other causes, such as AMD, PCV, fundus angioid streaks, or trauma
2. Presence of any other ophthalmic diseases
3. Prior treatment of CNV, including thermal laser photocoagulation, submacular surgery, intravitreal any anti-VEGF drugs, and photodynamic therapy (PDT)
4. Administration immunosuppressants or corticosteroids (local or systemic) in observation period
5. Presence of systemic diseases or pregnancy

Study & Design

• Study Type: Observational
• Study Design: Not specified